Macquarie Group’s Ocular Therapeutix OCUL Stock Holding History

Macquarie Group’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-174,389	Closed	-$2.04M	–	1290
2025 Q3	$2.04M	Sell	174,389 -67,650	-28%	-$809K	﹤0.01%	1164
2025 Q2	$2.25M	Sell	242,039 -2,945	-1%	-$23.1K	﹤0.01%	1186
2025 Q1	$1.8M	Buy	244,984 +234,436	+2,223%	+$1.8M	﹤0.01%	1255
2024 Q4	$90	Buy	+10,548	New	+$103K	﹤0.01%	1628
2022 Q2	–	Sell	-8,837	Closed	-$44K	–	2607
2022 Q1	$44K	Hold	8,837	–	–	﹤0.01%	2182
2021 Q4	$62K	Sell	8,837 -2,149	-20%	-$16.7K	﹤0.01%	2084
2021 Q3	$110K	Buy	10,986 +7,396	+206%	+$83.1K	﹤0.01%	1954
2021 Q2	$51K	Buy	3,590 +2,406	+203%	+$36.6K	﹤0.01%	2155
2021 Q1	$19K	Sell	1,184 -562	-32%	-$10.8K	﹤0.01%	2296
2020 Q4	$36K	Buy	+1,746	New	+$25.9K	﹤0.01%	2112
2018 Q1	–	Sell	-6,900	Closed	-$31K	–	2310
2017 Q4	$31K	Buy	+6,900	New	+$35.2K	﹤0.01%	2141

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macquarie Group's OCUL Position: Q4 2025 in Review

Macquarie Group sold out of Ocular Therapeutix (OCUL) in Q4 2025, closing a stake of 174,389 shares — an estimated $2.04M sold.

Macquarie Group first reported a position in OCUL in Q4 2017 and held it in 11 quarters. The position peaked at $2.25M in Q2 2025. 249 funds tracked by Wall St. Rank hold OCUL as of Q4 2025.

Macquarie Group reported no remaining Ocular Therapeutix position as of Q4 2025 after selling out during the quarter.
Macquarie Group sold 174,389 Ocular Therapeutix shares in Q4 2025, an estimated $2.04M.
Macquarie Group first reported a position in Ocular Therapeutix in Q4 2017 and held it in 11 quarters.
Macquarie Group's Ocular Therapeutix position peaked at $2.25M in Q2 2025.
249 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.